Compounds > rsr 4
Page last updated: 2024-11-07

rsr 4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid): allosteric effector of hemoglobin; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131347
CHEMBL ID166273
SCHEMBL ID6556141
MeSH IDM0207106

Synonyms (12)

Synonym
rsr 4
CHEMBL166273
2-[4-[2-(3,5-dichloroanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid
2-(4-(2-((3,5-dichlorophenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoic acid
131179-94-7
4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid)
rsr4
rsr-4
propanoic acid, 2-(4-(2-((3,5-dichlorophenyl)amino)-2-oxoethyl)phenoxy)-2-methyl-
SCHEMBL6556141
DTXSID80156933
AKOS040753841
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID226490Oxygen pressure in mmHg at which the control hemoglobin solution (in presence of 10 mM compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226489Oxygen pressure in mmHg at which the control hemoglobin solution (no compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226492Dose-response study in whole blood at a concentration of 0.5 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226496Dose-response study in whole blood at a concentration of 4.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226493Dose-response study in whole blood at a concentration of 1.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226494Dose-response study in whole blood at a concentration of 10.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID226491Allosteric activity evaluated as the ratio of the oxygen pressure in mmHg between hemoglobin-compound and compound-free hemoglobin (control) solution at which 50% oxygen saturation's are respectively attained.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors.
AID226495Dose-response study in whole blood at a concentration of 2.0 mM1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (87.50)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9910halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
propane
Propane: A three carbon alkane with the formula H3CCH2CH3.		2.0110alkane;
gas molecular entity		food propellant
bezafibrate
[no description available]		2.3820aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
efaproxiral
efaproxiral: RN & structure given in first source; allosteric effector of hemoglobin		2.6730
l 345
L 345: RN & structure given in first source		2.3820
l 35
L 35: a negative effector of hemoglobin; RN & structure given in first source		2.3820
lr 16
LR 16: structure given in first source; has potent effects on oxygen affinity of hemoglobin, on blood cholesterol and on low density lipoprotein		2.3820
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid
4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.		1.9810stilbenoid
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
A-Thalassemia
[description not available]		03.3811
alpha-Thalassemia
A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.		03.3811
Anemia, Cooley's
[description not available]		01.9910
beta-Thalassemia
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.		01.9910